13 February 2019
The U.S. Food and Drug Administration (FDA) recently released the final guidance entitled “Public Warning and Notification of Recalls.” The announcement of the guidance has been published in the Federal Register on February 8, 2019.
For the fiscal year 2018, FDA reports a total of 7,420 recalls with 831 that were classified as the highest risk. Acording to the agency, FDA will routinely provide more information on recalls and other safety issues that have happened and also communicate more frequently and, in many cases, directly to consumers through the agency’s social media. Therefore, the final guidance for industry and FDA staff
FDA states that in accordance with the draft version of this guidance, the agency already issued alerts or consumer warnings related to many products (including valsartan, losartan and irbesartan).
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The Health Ministry has added two new conditions to the list of rare diseases
14 May 2024
Novel preservation method could improve storage of biologics
14 May 2024
mRNA cancer vaccine granted world-first approval
13 May 2024
Life expectancy of Russians citizens should reach 81 years by 2036
13 May 2024